Showing 62,861 - 62,880 results of 63,536 for search '(( 01 ((0 decrease) OR (a decrease)) ) OR ( 50 ((ng decrease) OR (nn decrease)) ))', query time: 1.45s Refine Results
  1. 62861
  2. 62862
  3. 62863
  4. 62864
  5. 62865
  6. 62866
  7. 62867
  8. 62868

    CBF-1 suppresses WC-independent <i>frq</i> transcription by promoting the recruitment of the transcriptional co-repressor RCM-1. by Xuemei Cao (331331)

    Published 2018
    “…<p>(A, B) ChIP assays showing the enrichment of A) WC-1 and B) WC-2 is decreased and the peak of WC-1 binding is delayed in the <i>cbf-1</i><sup><i>KO</i></sup> strain compared to the wild-type strain. …”
  9. 62869
  10. 62870

    Table_1_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.xlsx by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  11. 62871

    DataSheet_1_GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.pdf by Xiaomiao Ye (13850284)

    Published 2022
    “…Moreover, compared with WT mice, GSDMD<sup>-/-</sup> mice showed reduced infarct size (25.45 ± 3.07% versus 36.47 ± 3.72%), improved left ventricular ejection fraction (37.71 ± 1.81% versus 29.44 ± 2.28%) and left ventricular fractional shortening (18.01 ± 0.97% versus 13.62 ± 1.15%) as well as attenuated pathological damage after I/R injury, along with reduced levels of proinflammatory cytokines and decreased infiltration of neutrophils.…”
  12. 62872

    Image_3_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  13. 62873

    Image_6_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  14. 62874

    Image_2_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  15. 62875

    Image_1_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  16. 62876

    Image_5_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  17. 62877

    Image_4_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

    Published 2023
    “…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”
  18. 62878

    Image_8.tif by Angelica Martins Batista (5086820)

    Published 2018
    “…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”
  19. 62879

    Image_1.tif by Angelica Martins Batista (5086820)

    Published 2018
    “…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”
  20. 62880

    Image_5.tif by Angelica Martins Batista (5086820)

    Published 2018
    “…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”